BCAX
Bicara Therapeutics Inc. Common Stock (BCAX) Economic Moat Analysis (2026)
Overall Score
Profitability Returns
TTM returns remain deeply negative, with ROA at -36.2%, ROE at -41.5%, and ROIC at -43.0%, indicating no evidence of durable pricing power or capital efficiency.
Margins are effectively zero across gross, operating, EBITDA, pretax, and net profit, showing the business is still not generating operating leverage.
Balance Sheet Financial Resilience
Liquidity remains very strong with a current ratio of 11.6x and cash ratio of 2.22x, supported by cash per share of $7.32.
Leverage is minimal, with debt-to-equity at 0.0025 and debt-to-assets at 0.23%, limiting balance-sheet risk despite ongoing losses.
Cash Flow Durability
Operating cash flow and free cash flow remain negative, with FCF yield at -8.5% and operating cash flow per share at -$1.99, indicating the moat is not yet translating into cash generation.
Cash conversion remains poor, with operating cash flow coverage ratios deeply negative and no sign of recurring excess cash flow.
Valuation Support
The stock screens at a low EV/sales and EV/EBITDA profile, but those multiples are not meaningful given zero revenue and negative EBITDA.
Price-to-book of 3.52x is not obviously cheap for a company with negative returns and no demonstrated earnings power.
Moat Evidence Competitive Positioning
There is still no observable moat evidence in the financials: zero margins, negative returns, and no revenue base to demonstrate scale advantages.
The balance sheet is intact, but the operating profile does not yet show durable differentiation, switching costs, or network effects.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Bicara Therapeutics Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

